Mylan achieves double-digit growth in second quarter of 2015

Mylan has announced its financial results for the second quarter of 2015, during which it delivered a revenue total of $2.37 billion (1.52 billion pounds).

This represented a year-on-year increase of 36 percent on a constant currency basis. Excluding the impact of the acquisition of Abbott's non-US developed markets specialty and branded generics business, total revenues increased 14 percent.

Its generics segment net sales were up 43 percent to $2.06 billion, thanks in large part to the acquisition of the Abbott assets, with profitability and earnings performance also improving.

Given its strong momentum, the company is raising its 2015 adjusted diluted earnings per share guidance range to $4.15 to $4.35, an increase of 19 percent, or 23 percent on a constant currency basis.

Mylan chief executive officer Heather Bresch said: "Our exceptional second-quarter results continue to underscore the underlying strength and diversity of our base business and our relentless focus on execution."

The company continues to make efforts to close a deal to acquire fellow generics manufacturer Perrigo.